STANDARD BIOTOOLS INC.LAB财报
Nasdaq · 医疗保健 · 实验室分析仪器
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
主要股东
| 股东 | 持股比例 | 股数 | 变动 | 截至 |
|---|---|---|---|---|
| NOS. OF ABOVE PERSONS | 18.59% | 69.0M | ▲ +1.30pp | 2024-08-14 |
| Viking Global Investors LP | 15.30% | 58.7M | ▲ +5.80pp | 2024-03-20 |
| BlackRock, Inc. | 6.00% | 22.5M | 无变化 | 2024-11-08 |
| The Vanguard Group | 4.65% | 17.3M | 无变化 | 2024-11-12 |
| Caligan Partners LP | 2.40% | 7.0M | — | 2024-01-08 |
| Millennium Management LLC | 1.90% | 7.0M | ▼ -3.30pp | 2024-10-21 |
| Indaba Capital Management, L.P. | 0.70% | 2.6M | ▼ -9.20pp | 2024-11-14 |
| s/ | — | 4.4M | — | 2024-01-12 |
内部人交易
Net 90d: +$0 · buys $0 / sells $0时间范围:
类型:
身份:
| 内部人 | 身份 | 类型 | ||||
|---|---|---|---|---|---|---|
| 2026-04-06 | Michael Egholm | President & CEO | Option exercise | 196.5K | $0.00 | $0 |
| 2026-04-06 | Kim Hanjoon Alex | Chief Financial Officer | Option exercise | 70.2K | $0.00 | $0 |
| 2026-03-20 | Michael Egholm | President & CEO | Grant | 1.04M | $0.00 | $0 |
| 2026-03-20 | Kim Hanjoon Alex | Chief Financial Officer | Grant | 323.2K | $0.00 | $0 |
| 2026-03-20 | Sean Mackay | SVP & Chief Business Officer | Grant | 272.1K | $0.00 | $0 |
| 2026-02-26 | Carey Thomas D. | Director | Grant | 51.3K | $1.17 | $60.0K |
| 2026-02-26 | Eli Casdin | Director | Grant | 53.0K | $1.17 | $62.0K |
| 2026-02-26 | Troy Cox | Director | Grant | 57.3K | $1.17 | $67.0K |
1–8 of 8